Moreover, over the last few years the approach to treatment of patients with a high cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie, glucocentricity or lipocentricity) to effective diagnostics, monitoring, and treatment of all risk factors and general cardiovascular risk as well as concomitant diseases, stressing the role of residual risk, and the intensity of the applied therapy. In the case of lipid disorders, intensive lipid-lowering treatment is currently recommended (and not just intensive statin treatment, as it has been for years) in order to achieve in our patients as low concentrations of low density lipoprotein (LDL) cholesterol as possible, according to the rule of “the lower the better”, but also to do it as soon as possible (“the earlier the better”) and maintain it as long as possible (“the longer the better”), as this gives us a chance to reduce the risk of cardiovascular events even in every other patient (50–55%)[6, 7]. Taking into consideration immense challenges still present in diagnostics and therapy of lipid disorders, changes in the approach to treatment, including innovative molecules, as well as the most recent results of numerous studies (lipidology and atherosclerosis research are currently the most rapidly developing specialty in medicine), Polish Lipid Association (PoLA), along with College of Family Physicians in Poland (CFPiP), Polish Cardiac Society (PCS), Polish Society of Diabetology (PSD), Polish Society of Laboratory Diagnostics (PSLD), and Polish Society of Hypertension (PSH), decided to prepare comprehensive guidelines concerning management of lipid disorders, with special attention paid to the practical aspect of these guidelines, as we would like to make them an actual tool for everyday work with patients suffering from lipid disorders.